Ferrlecite

Ferrlecite: a preparation containing iron

Ferrlecite is a pharmaceutical preparation that contains the active substance iron gluconate. It is used to treat iron deficiency anemia and to compensate for the body's increased need for iron, for example, during pregnancy, lactation, as well as during periods of growth and development.

The manufacturer of Ferrlecite is the Rhone-Poulenc Rohrer company from Germany. The drug is available as an injection solution containing 62.5 mg of active substance. It is intended for intramuscular or intravenous administration.

Ferrlecite is used to compensate for iron deficiency in the body, which helps normalize hemoglobin levels and improve the general condition of the patient. It is effective for iron deficiency anemia, which can occur both as a result of insufficient intake of iron from food and due to impaired absorption of iron in the body.

Before starting treatment with Ferrlecite, contraindications must be taken into account. The drug is not recommended for use in case of hypersensitivity to iron preparations, as well as in hemochromatosis, hemosiderosis and hemolytic anemia.

Some side effects may occur when using Ferrlecite. Dyspeptic symptoms such as nausea, vomiting, constipation and diarrhea may occur when taking the drug. Flushing of the skin, dizziness, back or abdominal pain, difficulty breathing and a transient decrease in blood pressure may also occur.

It is necessary to take into account the possible interaction of Ferrlecite with other drugs. For example, it may interfere with the absorption of tetracyclines, so they should be administered at least two hours before or after taking iron gluconate. In addition, the absorption of iron from the gastrointestinal tract can be negatively affected by eggs, milk, tea and antacids.

In case of Ferrlecite overdose, symptoms such as abdominal pain, vomiting, diarrhea, constipation, gastrointestinal irritation, lethargy, weak pulse and hypotension may occur. If signs of peripheral circulatory collapse appear, they may appear within 30 minutes after taking the drug or may be delayed for several hours.

When prescribing Ferrlecite to patients with gastric ulcers, when prescribing Ferrlecite to patients with gastric ulcers, erosive gastritis or inflammatory diseases of the gastrointestinal tract, one must be careful and evaluate the benefits of treatment compared to the possible risks. You should also consult your doctor if the patient is taking other medications or has any underlying medical conditions.

It is important to note that this information is current as of my last update in September 2021 and changes may be made regarding Ferrlecite, its uses and recommendations. For the most accurate and up-to-date information, it is recommended that you consult your healthcare professional or pharmacist.